Milbank LLP advised the shareholders of Coriolis Pharma on an investment by KKR. Coriolis Pharma secures the financial investment by KKR, a leading global investment firm, to further expand its global footprint and realize its next steps in growth.
Coriolis Pharma is a globally operating contract research and development organization (CRDO) and a world leader in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. Coriolis Pharma’s vision is to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. Established in 2008, Coriolis Pharma has a main office in Martinsried near Munich, and over 200 people from over 36 nations are employed worldwide.
The Milbank team that advised the shareholders of Coriolis Pharma on the corporate and tax aspects of the transaction was led by partner Michael Bernhardt (Corporate/M&A) and included partner Matthias Schell (Tax) as well as special counsel Sebastian Dexheimer and associates Sarah-Maria Resch, Steffen Post, Josephine Schuster (all Corporate/M&A) and Arne Hammerich (Tax).
